



1643 IFW

PATENT
ATTORNEY DOCKET NO. 01948/089002

Certificate of Mailing: Date of Deposit: October 11, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Rosemarie Perullo
Printed name of person mailing correspondence

Rosemarie Perullo
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Aird et al.

Confirmation No.: 5758

Serial No.: 10/542,717

Art Unit: 1643

Filed: December 1, 2005

Examiner: Alana Harris

Customer No.: 21559

Title: ENDOCAN COMPOSITIONS AND METHODS FOR THE
TREATMENT OF NEOPLASMS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. A copy of a search report from a corresponding international application is also enclosed.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.


Date: October 11, 2006

Respectfully submitted,



Kristina Bieker Brady
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

Sheet 1 of 2

| | | |
|--|---------------------|------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b)) | Attorney Docket No. | 01948/089002 |
| | Serial No. | 10/542,717 |
| | Applicant | Aird et al. |
| | Filing Date | December 1, 2005 |
| | Group | 1643 |
| | IDS Filed | October 11, 2006 |

| U.S. PATENT DOCUMENTS | | | | | | |
|---|---|------------------|--------------------------|-------|----------|------------------------------|
| Examiner's Initials | Document Number | Publication Date | Patentee or Applicant | Class | Subclass | Filing Date (If Appropriate) |
| | 2003/0109434 | 06-12-2003 | Algate et al. | | | |
| | 2003/0152926 | 08-14-2003 | Murray et al. | | | |
| | 6,670,328 | 12-30-2003 | Lassalle et al. | | | |
| FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION | | | | | | |
| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation (Yes/No) |
| | FR 2816214 | May 10, 2002 | France | | | Abstract Only |
| | FR 2816410 | May 10, 2002 | France | | | Abstract Only |
| | WO 02/38178 A1 | May 16, 2002 | WIPO | | | Abstract Only |
| | WO 02/39123 A1 | May 16, 2002 | WIPO | | | Abstract Only |
| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) | | | | | | |
| | Aitkenhead et al., "Identification of Endothelial Cell Genes Expressed in an In Vitro Model of Angiogenesis: Induction of ESM-1, (beta)ig-h3, and NrCAM," <i>Microvasc. Res.</i> 63:159-171 (2002). | | | | | |
| | Bécharde et al., "Human Endothelial-Cell Specific Molecule-1 Binds Directly to the Integrin CD11a/CD18 (LFA-1) and Blocks Binding to Intercellular Adhesion Molecule-1," <i>J. Immunol.</i> 167:3099-3106 (2001). | | | | | |
| | Bécharde et al., "Characterization of the Secreted Form of Endothelial-Cell-Specific Molecule 1 by Specific Monoclonal Antibodies," <i>J. Vasc. Res.</i> 37:417-425 (2000). | | | | | |
| | Bécharde et al., "Endocan Is a Novel Chondroitin Sulfate/Dermatan Sulfate Proteoglycan That Promotes Hepatocyte Growth Factor/Scatter Factor Mitogenic Activity," <i>J. Biol. Chem.</i> 276:48341-48349 (2001). | | | | | |
| | Carson-Walter et al., "Cell Surface Tumor Endothelial Markers Are Conserved in Mice and Humans," <i>Cancer Res.</i> 61:6649-6655 (2001). | | | | | |
| | Dube et al., "ELF-1 Is a Transcriptional Regulator of the Tie2 Gene During Vascular Development," <i>Circ. Res.</i> 88:237-244 (2001). | | | | | |
| | Englisch and Gauss, "Chemically Modified Oligonucleotides as Probes and Inhibitors," <i>Angew. Chem. Int. Ed. Eng.</i> 30:613-629 (1991). | | | | | |

| | |
|---|-----------------|
| EXAMINER | DATE CONSIDERED |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | |

| | | |
|--|---------------------|------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b)) | Attorney Docket No. | 01948/089002 |
| | Serial No. | 10/542,717 |
| | Applicant | Aird et al. |
| | Filing Date | December 1, 2005 |
| | Group | 1643 |
| | IDS Filed | October 11, 2006 |

| | |
|--|--|
| | Folkman, "Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease," <i>Nat. Med.</i> 1:27-31 (1995). |
| | Haspel et al., "Inhibition of Vascular Endothelial Growth Factor-Associated Tyrosine Kinase Activity with SU5416 Blocks Sprouting in the Microvascular Endothelial Cell Spheroid Model of Angiogenesis," <i>Microvasc. Res.</i> 63:304-315 (2002). |
| | Lassalle et al., "ESM-1 is a Novel Human Endothelial Cell-Specific Molecule Expressed in Lung and Regulated by Cytokines," <i>J. Biol. Chem.</i> 271:20458-20464 (1996). |
| | Lin et al., "Antiangiogenic Gene Therapy Targeting the Endothelium-Specific Receptor Tyrosine Kinase Tie2," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 95:8829-8834 (1998). |
| | Montgomery et al., "RNA as a Target of Double-Stranded RNA-Mediated Genetic Interference in <i>Caenorhabditis elegans</i> ," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 95:15502-15507 (1998). |
| | Opavsky et al., "Molecular Characterization of the Mouse <i>Tem1/endosialin</i> Gene Regulated by Cell Density In Vitro and Expressed in Normal Tissues In Vivo," <i>J. Biol. Chem.</i> 276:38795-38807 (2001). |
| | Paul et al., "Effective Expression of Small Interfering RNA in Human Cells," <i>Nat. Biotechnol.</i> 20:505-508 (2002). |
| | Scanlon et al., "Oligonucleotide-Mediated Modulation of Mammalian Gene Expression," <i>FASEB J.</i> 9:1288-1296 (1995). |
| | Scherpereel et al., "Overexpression of Endocan Induces Tumor Formation," <i>Cancer Res.</i> 63:6084-6089 (2003). |
| | Schlaeger et al., "Uniform Vascular-Endothelial-Cell-Specific Gene Expression in Both Embryonic and Adult Transgenic Mice," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 94:3058-3063 (1997). |
| | Shih et al., "Molecular Profiling of Angiogenesis Markers," <i>Am. J. Pathol.</i> 161:35-41 (2002). |
| | St. Croix et al., "Genes Expressed in Human Tumor Endothelium," <i>Science</i> 289:1197-1202 (2000). |
| | Wang et al., "PG25, a Pineal-Specific cDNA, Cloned by Differential Display PCR (DDPCR) and Rapid Amplification of cDNA Ends (RACE)," <i>J. Neurosci. Methods</i> 73:187-191 (1997). |

| | |
|---|-----------------|
| EXAMINER | DATE CONSIDERED |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | |